Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus ANGIOVIST 292.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus ANGIOVIST 292.
ANGIO-CONRAY vs ANGIOVIST 292
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Angiovist 292 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolar iodinated contrast agent. It functions by absorbing x-rays due to the high atomic number of iodine, thereby enhancing the radiopacity of vascular structures and organs during diagnostic imaging. It also increases the osmolarity of the intravascular compartment, which can lead to hemodynamic effects.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
Intravenous administration: 50-150 mL of a 292 mg iodine/mL solution for adults, depending on the imaging procedure, with a maximum total dose of 300 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal; >90% of dose excreted unchanged in urine within 24 hours. Fecal excretion is negligible (<1%).
Category C
Category C
Contrast Agent
Contrast Agent